Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Increase in Short Interest

Context Therapeutics Inc. (NASDAQ:CNTX) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 40,400 shares, an increase of 260.7% from the March 31st total of 11,200 shares. Based on an average daily trading volume, of 55,500 shares, the short-interest ratio is currently 0.7 days. Currently, 0.3% of the shares of the company are sold short.

Context Therapeutics Trading Up 2.2 %

NASDAQ:CNTX traded up $0.03 during trading hours on Friday, reaching $1.41. The company had a trading volume of 19,984 shares, compared to its average volume of 51,268. Context Therapeutics has a 1-year low of $0.47 and a 1-year high of $1.69. The business’s 50 day moving average price is $1.25 and its 200-day moving average price is $1.13.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.07). As a group, analysts forecast that Context Therapeutics will post -1.38 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Context Therapeutics stock. Affinity Asset Advisors LLC lifted its holdings in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 22.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 328,817 shares of the company’s stock after buying an additional 61,243 shares during the quarter. Affinity Asset Advisors LLC owned approximately 2.06% of Context Therapeutics worth $497,000 as of its most recent SEC filing. Institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their target price on Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.